GRNA News and Press, GreenLight Biosciences Holdings PBC From 01/09/23

The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine design Epivax Therapeutics, Inc. will contribute a proprietary set of immunoinformatics tools for rapidly identifying and diff...

Shares of Greenlight Biosciences (NASDAQ: GRNA) were down 13.4% as of the market close on Thursday. The decline appears to be the result of a Bloomberg Dealreporter report that said the drugmaker turned down an opportunity for a private-equity firm to take it private. Greenlight's sha...

GreenLight Biosciences ( NASDAQ: GRNA ) rose 2.4% after a report that the biotech company has turned away some private equity approaches. Greenlight ( GRNA ) turned down the offers as it would like to remain public and would partner with other companies, according to a Dealrep...

GreenLight Biosciences press release ( NASDAQ: GRNA ): Q3 GAAP EPS of -$0.27. Revenue of $1.73M (+380.6% Y/Y). The company estimates that its cash and equivalents of $98.4M as of September 30, 2022 will be sufficient to fund planned operating expenses and capital expen...

Working toward clinical trial initiation for COVID vaccine candidate in 2023 Shingles vaccine candidate selection planned for 2023 in partnership with Serum Institute of India Calantha™, Colorado potato beetle solution, commercial launch planned for 2023, subject to regulat...

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world’s toughest problems in human health and agriculture, today announced that Dr. Andrey Zarur, CEO, and ...

GreenLight Biosciences ( NASDAQ: GRNA )is eliminating 25% of its workforce as part of a realignment to support R&D in its research, development and commercialization of its plant health and human health pipelines. On the human health front, the company will focus o...

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, tod...

GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armyworm Fall armyworm is one of the most destructive insect pests on the planet, causing more than US$2 billion in annual crop loss worldwide The A...

GreenLight Biosciences press release ( NASDAQ: GRNA ): Q2 GAAP EPS of -$0.42. Revenue of $1.77M (+261.2% Y/Y). Cash, cash equivalents, and marketable securities were $44.1 million as of June 30, 2022, compared to $31.4 million as of December 31, 2021. For further...